| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10005041 | HBV | ENSG00000155511.19 | protein_coding | GRIA1 | No | No | 2890 | P42261 |
| TVIS10005042 | HBV | ENSG00000155511.19 | protein_coding | GRIA1 | No | No | 2890 | P42261 |
| TVIS10034071 | HBV | ENSG00000155511.19 | protein_coding | GRIA1 | No | No | 2890 | P42261 |
| TVIS10051034 | HBV | ENSG00000155511.19 | protein_coding | GRIA1 | No | No | 2890 | P42261 |
| TVIS10050959 | HBV | ENSG00000155511.19 | protein_coding | GRIA1 | No | No | 2890 | P42261 |
| TVIS30086592 | HIV | ENSG00000155511.19 | protein_coding | GRIA1 | No | No | 2890 | P42261 |
| TVIS30086040 | HIV | ENSG00000155511.19 | protein_coding | GRIA1 | No | No | 2890 | P42261 |
| TVIS30083783 | HIV | ENSG00000155511.19 | protein_coding | GRIA1 | No | No | 2890 | P42261 |
| TVIS30063832 | HIV | ENSG00000155511.19 | protein_coding | GRIA1 | No | No | 2890 | P42261 |
| TVIS30063833 | HIV | ENSG00000155511.19 | protein_coding | GRIA1 | No | No | 2890 | P42261 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | GRIA1 |
|---|---|
| DrugBank ID | DB00142 |
| Drug Name | Glutamic acid |
| Target ID | BE0000640 |
| UniProt ID | P42261 |
| Regulation Type | |
| PubMed IDs | 17139284; 17016423; 1279377; 7679210; 7838123 |
| Citations | Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Stein E, Cox JA, Seeburg PH, Verdoorn TA: Complex pharmacological properties of recombinant alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor subtypes. Mol Pharmacol. 1992 Nov;42(5):864-71.@@Henley JM, Jenkins R, Hunt SP: Localisation of glutamate receptor binding sites and mRNAs to the dorsal horn of the rat spinal cord. Neuropharmacology. 1993 Jan;32(1):37-41.@@Li F, Owens N, Verdoorn TA: Functional effects of mutations in the putative agonist binding region of recombinant alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Mol Pharmacol. 1995 Jan;47(1):148-54. |
| Groups | Approved; Nutraceutical |
| Direct Classification | Glutamic acid and derivatives |
| SMILES | N[C@@H](CCC(O)=O)C(O)=O |
| Pathways | Histidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); 3-Methylglutaconic Aciduria Type I; beta-Ketothiolase Deficiency; Purine Nucleoside Phosphorylase Deficiency; Tyrosine Metabolism; Ketoprofen Action Pathway; Glutamate Metabolism; Argininosuccinic Aciduria; Salla Disease/Infantile Sialic Acid Storage Disease; Tyrosinemia Type I; Hyperinsulinism-Hyperammonemia Syndrome; 2-Methyl-3-hydroxybutryl-CoA Dehydrogenase Deficiency; Glutaric Aciduria Type I; Propanoate Metabolism; Celecoxib Action Pathway; Glycine and Serine Metabolism; Suprofen Action Pathway; Indomethacin Action Pathway; Carbamoyl Phosphate Synthetase Deficiency; Sialuria or French Type Sialuria; Ibuprofen Action Pathway; Saccharopinuria/Hyperlysinemia II; Histidine Metabolism; Arginine and Proline Metabolism; Purine Metabolism; Diflunisal Action Pathway; Etodolac Action Pathway; Ammonia Recycling |
| PharmGKB | PA449776 |
| ChEMBL | CHEMBL575060 |
